Moleculin Biotech, Inc. (MBRX)
Healthcare · NCM · US
Price as at 30 Sept 2026, 21:06 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Moleculin Biotech, Inc. trades at $0.50. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 10 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 0.0 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
MBRX dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
MBRX earnings and analyst estimates
Recommendation mix, 3 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
MBRX passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
MBRX peers
The largest companies in the same industry (Biotechnology), then in the same sector.
- CSLLY CSL Limited
- RVMD Revolution Medicines, Inc.
- CMXHF CSL Limited
- ALNY Alnylam Pharmaceuticals, Inc.
- RPRX Royalty Pharma plc
- INCY Incyte Corporation
- INSM Insmed Incorporated
- GNMSF Genmab A/S
Every healthcare company we cover is on the Healthcare hub.
Common questions
What is MBRX's P/E ratio?
MBRX trades at 0.0 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its MBRX data?
Fundamentals for MBRX come from company filings and exchange data, as listed on NCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:06 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for MBRX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.